{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:45:13Z","timestamp":1776174313502,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1197169"],"award-info":[{"award-number":["GNT1197169"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-026-03803-z","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:51:03Z","timestamp":1776171063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proportions of patients meeting definitions for progressive disease or improvement should be included in clinical trials for systemic sclerosis interstitial lung disease"],"prefix":"10.1186","volume":"28","author":[{"given":"Kathleen","family":"Morrisroe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Tashkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray","family":"Baron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"10","key":"3803_CR1","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","volume":"200","author":"A-M Hoffmann-Vold","year":"2019","unstructured":"Hoffmann-Vold A-M, Fretheim H, Halse A-K, et al. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. Am J Respir Crit Care Med. 2019;200(10):1258\u201366.","journal-title":"Am J Respir Crit Care Med"},{"key":"3803_CR2","doi-asserted-by":"publisher","unstructured":"Hoffmann-VoldA-M, Allanore Y, Alves M et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2020;80(2):219\u2013227. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217455.","DOI":"10.1136\/annrheumdis-2020-217455"},{"issue":"8","key":"3803_CR3","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1093\/rheumatology\/kez532","volume":"59","author":"K Morrisroe","year":"2020","unstructured":"Morrisroe K, Stevens W, Sahhar J, Ngian GS, Ferdowsi N, Hansen D, Patel S, Hill CL, Roddy J, Walker J, Proudman S, Nikpour M. The clinical and economic burden of systemic sclerosis related interstitial lung disease. Rheumatology (Oxford). 2020;59(8):1878\u201388.","journal-title":"Rheumatology (Oxford)"},{"issue":"13","key":"3803_CR4","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMp1500526","volume":"372","author":"BA Karimi-Shah","year":"2015","unstructured":"Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis\u2013FDA review of pirfenidone and nintedanib. N Engl J Med. 2015;372(13):1189\u201391. https:\/\/doi.org\/10.1056\/NEJMp1500526.","journal-title":"N Engl J Med"},{"key":"3803_CR5","doi-asserted-by":"crossref","unstructured":"Raghu G, Montesi SB, Silver RM, Hossain T, Macrea M, Herman D, Barnes H, Adegunsoye A, Azuma A, Chung L, et al. Treatment of systemic sclerosis\u2013associated interstitial lung disease: evidence-based recommendations. An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2024;209(2):137\u201352.","DOI":"10.1164\/rccm.202306-1113ST"},{"issue":"25","key":"3803_CR6","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655\u201366. https:\/\/doi.org\/10.1056\/NEJMoa055120.","journal-title":"N Engl J Med"},{"issue":"9","key":"3803_CR7","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708\u201319. https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7.","journal-title":"Lancet Respir Med"},{"issue":"26","key":"3803_CR8","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1903076.","journal-title":"N Engl J Med"},{"issue":"12","key":"3803_CR9","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1136\/ard-2022-222564","volume":"81","author":"Y Allanore","year":"2022","unstructured":"Allanore Y, Vonk MC, Distler O, Azuma A, Mayes MD, Gahlemann M, et al. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON. Ann Rheum Dis. 2022;81(12):1722\u20139. https:\/\/doi.org\/10.1136\/ard-2022-222564.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3803_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","volume":"9","author":"KB Highland","year":"2021","unstructured":"Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med. 2021;9(1):96\u2013106. https:\/\/doi.org\/10.1016\/S2213-2600(20)30330-1.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"3803_CR11","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/art.41668","volume":"73","author":"D Roofeh","year":"2021","unstructured":"Roofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, Denton CP, et al. Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 2021;73(7):1301\u201310. https:\/\/doi.org\/10.1002\/art.41668.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3803_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. The Lancet Respiratory Medicine. 2023;11(1):45\u201354. https:\/\/doi.org\/10.1016\/S2213-2600(22)00359-9.","journal-title":"The Lancet Respiratory Medicine"},{"issue":"5","key":"3803_CR13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","volume":"40","author":"N Acharya","year":"2020","unstructured":"Acharya N, Sharma SK, Mishra D, Dhooria S, Dhir V, Jain S. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial. Rheumatol Int. 2020;40(5):703\u201310. https:\/\/doi.org\/10.1007\/s00296-020-04565-w.","journal-title":"Rheumatol Int"},{"issue":"7","key":"3803_CR14","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","volume":"3","author":"S Ebata","year":"2021","unstructured":"Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2021;3(7):e489\u201397. https:\/\/doi.org\/10.1016\/S2665-9913(21)00107-7.","journal-title":"Lancet Rheumatol"},{"key":"3803_CR15","unstructured":"Kuzumi A, Ebata S, Baron M, Sato S, Yoshizaki A. Usefulness of rituximab for the treatment of systemic sclerosis-associated interstitial lung disease: Further analysis of the DESIRES trial. J Am Acad Dermatol. 2025:S0190-9622(25)00196-3."},{"issue":"7","key":"3803_CR16","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1016\/S2665-9913(25)00068-2","volume":"7","author":"K Morrisroe","year":"2025","unstructured":"Morrisroe K, Barron M. Why is progressive ILD in systemic sclerosis so difficult to predict? Lancet Rheumatol. 2025;7(7):e452\u20133. https:\/\/doi.org\/10.1016\/S2665-9913(25)00068-2.","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"3803_CR17","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"3803_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","volume":"8","author":"AU Wells","year":"2020","unstructured":"Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8(5):453\u201360. https:\/\/doi.org\/10.1016\/S2213-2600(20)30036-9.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"3803_CR19","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1164\/rccm.201709-1845OC","volume":"197","author":"S Kafaja","year":"2018","unstructured":"Kafaja S, Clements P, Wilhalme H, Tseng C-H, Furst DE, Kim GH, et al. Reliability and minimally clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS-I and SLS-II). Am J Respir Crit Care Med. 2018;197(5):644\u201352.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"3803_CR20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00198-008-0559-5","volume":"19","author":"B Dawson-Hughes","year":"2008","unstructured":"Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, Khosla S, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19(4):449\u201358. https:\/\/doi.org\/10.1007\/s00198-008-0559-5.","journal-title":"Osteoporos Int"},{"issue":"4","key":"3803_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00198-007-0550-6","volume":"19","author":"AN Tosteson","year":"2008","unstructured":"Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19(4):437\u201347. https:\/\/doi.org\/10.1007\/s00198-007-0550-6.","journal-title":"Osteoporos Int"},{"issue":"1","key":"3803_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.11005\/jbm.2017.24.1.37","volume":"24","author":"JH Byun","year":"2017","unstructured":"Byun JH, Jang S, Lee S, Park S, Yoon HK, Yoon BH, et al. The efficacy of bisphosphonates for prevention of osteoporotic fracture: an update meta-analysis. J Bone Metab. 2017;24(1):37\u201349.","journal-title":"J Bone Metab"},{"key":"3803_CR23","doi-asserted-by":"crossref","unstructured":"Christopher W. Reconsidering the benefits of osteoporosis treatment: the case of bisphosphonates. Goodman, Christopher W. Am J Med. 2024;137(6):476\u2013478.","DOI":"10.1016\/j.amjmed.2024.02.012"},{"issue":"3","key":"3803_CR24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40618-023-02219-9","volume":"47","author":"M Schini","year":"2024","unstructured":"Schini M, Johansson H, Harvey NC, Lorentzon M, Kanis JA, McCloskey EV. An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. J Endocrinol Invest. 2024;47(3):501\u201311.","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"3803_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00198-007-0550-6","volume":"19","author":"AN Tosteson","year":"2008","unstructured":"Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19(4):437\u201347.","journal-title":"Osteoporos Int"},{"issue":"39","key":"3803_CR26","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.221647","volume":"195","author":"SN Morin","year":"2023","unstructured":"Morin SN, Feldman S, Funnell L, Giangregorio L, Kim S, McDonald-Blumer H, et al. Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update. CMAJ. 2023;195(39):E1333-E1348. https:\/\/doi.org\/10.1503\/cmaj.221647.","journal-title":"CMAJ"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03803-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03803-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03803-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:51:05Z","timestamp":1776171065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03803-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3803"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03803-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}